---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-158751"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:09:09.221120+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043

## Summary
- USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.
- Patent protection extends to July 2043, over 9 years beyond prior second-generation patent expiration in 2034.
- Nine total patents now issued or allowed by USPTO covering obicetrapib and its uses.
- Patent eligible for listing in FDA Orange Book as drug substance patent if product approved.

## SEC filing metadata
- accession: 0001193125-24-158751
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/0001193125-24-158751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/d851893d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-158751
- JSON: https://secwatch.observer/filing/0001193125-24-158751.json
- Plain text: https://secwatch.observer/filing/0001193125-24-158751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.